{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:45:08Z","timestamp":1782279908383,"version":"3.54.5"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Office of the Assistant Secretary for Preparedness and Response"},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201700020C"],"award-info":[{"award-number":["HHSO100201700020C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Elucidating the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load and clinical outcomes is critical for understanding coronavirus disease 2019 (COVID-19).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The SARS-CoV-2 levels were analyzed by quantitative real-time polymerase chain reaction (RT-qPCR) of nasopharyngeal or oropharyngeal swab specimens collected at baseline, and clinical outcomes were recorded over 60 days from 1362 COVID-19 hospitalized patients enrolled in a multicenter, randomized, placebo-controlled phase 2\/3 trial of sarilumab for COVID-19 (ClinicalTrials.gov NCT04315298).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In post hoc analyses, higher baseline viral load, measured by both RT-qPCR cycle threshold and log10 copies\/mL, was associated with greater supplemental oxygenation requirements and disease severity at study entry. Higher baseline viral load was associated with higher mortality, lower likelihood of improvement in clinical status and supplemental oxygenation requirements, and lower rates of hospital discharge. Viral load was not impacted by sarilumab treatment over time versus placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data support viral load as an important determinant of clinical outcomes in hospitalized patients with COVID-19 requiring supplemental oxygen or assisted ventilation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiab445","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T11:17:50Z","timestamp":1631099870000},"page":"1830-1838","source":"Crossref","is-referenced-by-count":24,"title":["Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2\/3 Trial"],"prefix":"10.1093","volume":"224","author":[{"given":"Anita","family":"Boyapati","sequence":"first","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F","family":"Wipperman","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Ehmann","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hamon","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Lederer","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpana","family":"Waldron","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Karayusuf","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafia","family":"Bhore","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C","family":"Nivens","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer D","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giane","family":"Sumner","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumathi","family":"Sivapalasingam","sequence":"additional","affiliation":[{"name":"Excision BioTherapeutics, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"2021120504473159900_CIT0001","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"2021120504473159900_CIT0002","doi-asserted-by":"crossref","first-page":"m1443","DOI":"10.1136\/bmj.m1443","article-title":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study","volume":"369","author":"Zheng","year":"2020","journal-title":"BMJ"},{"key":"2021120504473159900_CIT0003","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1038\/s41467-020-19057-5","article-title":"SARS-CoV-2 viral load is associated with increased disease severity and mortality","volume":"11","author":"Fajnzylber","year":"2020","journal-title":"Nat Commun"},{"key":"2021120504473159900_CIT0004","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1513\/AnnalsATS.202008-931RL","article-title":"Association of SARS-CoV-2 genomic load with outcomes in patients with COVID-19","volume":"18","author":"Zacharioudakis","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2021120504473159900_CIT0005","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2021120504473159900_CIT0006","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"2021120504473159900_CIT0007","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccell.2020.09.007","article-title":"SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19","volume":"38","author":"Westblade","year":"2020","journal-title":"Cancer Cell"},{"key":"2021120504473159900_CIT0008","doi-asserted-by":"crossref","first-page":"ciaa851","DOI":"10.1093\/cid\/ciaa851","article-title":"Impact of SARS-CoV-2 viral","author":"Magleby","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021120504473159900_CIT0009","article-title":"A randomized placebo-controlled trial of sarilumab in hospitalized patients with Covid-19 [preprint","author":"Sivapalasingam","year":"2021","journal-title":"medRxiv"},{"key":"2021120504473159900_CIT0010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/1740774517697919","article-title":"Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization","volume":"14","author":"Peterson","year":"2017","journal-title":"Clin Trials"},{"key":"2021120504473159900_CIT0011","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ajpath.2020.07.001","article-title":"Association of initial viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and symptoms","volume":"190","author":"Argyropoulos","year":"2020","journal-title":"Am J Pathol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab445\/41026435\/jiab445.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/11\/1830\/41429476\/jiab445.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/11\/1830\/41429476\/jiab445.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T04:48:47Z","timestamp":1638679727000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/11\/1830\/6366357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":11,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,9,8]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab445","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,9,8]]}}}